Betting the Farm: The Untold Origin Story of Agricultural Biotechnology

A Review of “Betting the Farm: How a Maverick Entrepreneur and a Band of Scientists Changed Agriculture Forever” by Dr. Adrienne E. Clarke and Dr. Janice Kimpel

In October 1982, twenty-three of the world’s leading plant molecular biologists arrived at a luxury resort in Scottsdale, Arizona. They had been summoned from universities in the United States, the United Kingdom, the Netherlands, Germany, and Australia by a man most of them had never heard of six months earlier. His name was David Padwa, a Bronx-born lawyer with a photographic memory and a hobby of reading Nature and Science the way other people read novels.

He had a conviction that molecular biology was about to do for agriculture what it was already doing for medicine — and the equivalent of $300 million in today’s dollars to prove it.

Betting the Farm, by Dr. Adrienne E. Clarke and Dr. Janice Kimpel, is the inside story of what happened next. Clarke was one of the twenty-three in the room that morning. Her firsthand vantage, combined with extensive archival research and interviews with Padwa himself before his death in 2023, gives the book a rare double perspective — boardroom and laboratory bench — on a chapter of business and scientific history that has gone largely untold.

The company Padwa founded was Agrigenetics. With his partners Gene Keluche, a Harvard MBA, and Gilbert de Botton, head of the Rothschilds bank in Switzerland, he raised his audacious sum not through venture capital but through a Research and Development Limited Partnership — a tax-advantaged structure that no other startup of the era could match. The money funded a global cohort of academic scientists charged with discovering useful genes and engineering them into seeds. It was work whose first commercial product would not reach the market for another fourteen years.

What follows is a story Clarke and Kimpel tell with remarkable honesty. There are takeover offers, warring shareholders, a failed IPO, soaring interest rates, government interventions that no investor memo could have modeled, and the daily judgment calls of running a company built around science that had not yet been invented. Agrigenetics did not survive these forces intact; it was crippled by them, and sold to Lubrizol in 1985. But the authors are clear-eyed about what that outcome means and doesn’t mean. Every investor came out whole. Padwa’s original vision missed its timeline by years — yet many of the technologies and basic discoveries that emerged from Agrigenetics’ laboratories are embedded in the commercial crops growing on millions of acres today.

The book’s deeper legacy may be the one the founders never planned for. The contracted scientists, Clarke among them, went back to their universities transformed — fluent in patent law, intellectual property strategy, and the language of business — and quietly reshaped how academic institutions came to view commercialization itself.

Betting the Farm is at once a portrait of a singular American entrepreneur, a case study in capitalizing technological possibility long before the market is ready for it, and a meditation on the unexpected pathways by which a bold bet — even one that misses its stated target — can change an entire field. For founders, investors, scientists, and anyone working at the frontier of long-horizon technology, it is essential reading.

Nicole Killian